Synera is a drug owned by Galen Specialty Pharma Us Llc. It is protected by 7 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 07, 2020. Details of Synera's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6465709 | Exothermic bandage |
Jul, 2020
(4 years ago) |
Expired
|
| US5658583 | Apparatus and methods for improved noninvasive dermal administration of pharmaceuticals |
Jul, 2015
(9 years ago) |
Expired
|
| US5919479 | Noninvasive dermal anesthetics |
Jul, 2015
(9 years ago) |
Expired
|
| US6546281 | Integrated apparatus for controlled heat aided dermal drug delivery |
Jul, 2015
(9 years ago) |
Expired
|
| US6306431 | Apparatus for heating to a desired temperature for improved administration of pharmaceutically active compounds |
Jul, 2015
(9 years ago) |
Expired
|
| US6465006 | Method for facilitating absorption of pharmaceutically active compounds |
Jul, 2015
(9 years ago) |
Expired
|
| US6780426 | Method and apparatus for improved heat controlled administration of pharmaceuticals |
Jul, 2015
(9 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Synera's patents.
Latest Legal Activities on Synera's Patents
Given below is the list of recent legal activities going on the following patents of Synera.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 16 Sep, 2016 | US6780426 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 04 Mar, 2008 | US6780426 |
| Recordation of Patent Grant Mailed Critical | 24 Aug, 2004 | US6780426 |
| Patent Issue Date Used in PTA Calculation Critical | 24 Aug, 2004 | US6780426 |
| Issue Notification Mailed Critical | 05 Aug, 2004 | US6780426 |
| Receipt into Pubs | 23 Jul, 2004 | US6780426 |
| Dispatch to FDC | 21 Jul, 2004 | US6780426 |
| Application Is Considered Ready for Issue Critical | 02 Jul, 2004 | US6780426 |
| Issue Fee Payment Received Critical | 14 Jun, 2004 | US6780426 |
| Issue Fee Payment Verified Critical | 14 Jun, 2004 | US6780426 |
US patents provide insights into the exclusivity only within the United States, but Synera is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Synera's family patents as well as insights into ongoing legal events on those patents.
Synera's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Synera's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 07, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Synera Generics:
There are no approved generic versions for Synera as of now.
Alternative Brands for Synera
There are several other brand drugs using the same active ingredient (Lidocaine; Tetracaine) as Synera. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Crescita Therap |
|
About Synera
Synera is a drug owned by Galen Specialty Pharma Us Llc. Synera uses Lidocaine; Tetracaine as an active ingredient. Synera was launched by Galen Specialty in 2005.
Approval Date:
Synera was approved by FDA for market use on 23 June, 2005.
Active Ingredient:
Synera uses Lidocaine; Tetracaine as the active ingredient. Check out other Drugs and Companies using Lidocaine; Tetracaine ingredient
Dosage:
Synera is available in patch form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 70MG;70MG | PATCH | Discontinued | TOPICAL |